Cite

HARVARD Citation

    Orringer, D. et al. (n.d.). First in Human Phase I Trial of Dual Vector (HSV1‐TK, Flt3L) Immunotherapy For The Treatment of Newly Diagnosed High‐Grade Glioma: Initial Results. Neurosurgery. p. . [Online]. 
  
Back to record